Miao Xu is the founder and CEO of Monexus and the foundational IP owner behind its engineered living materials. His research career has been building toward exactly the problem the company exists to solve.
A researcher at the University of Hong Kong, his published work centres on living materials and antimicrobial biomaterials — bio-inspired redox-cycling antimicrobial films (Biomaterials, 2018), dual-functional antimicrobial surface coatings (ACS Applied Materials & Interfaces, 2017), phage-derived depolymerases as antibiotic adjuvants (Frontiers in Microbiology, 2022), and mussel-inspired contact-active hydrogels (ACS Applied Bio Materials, 2019).
His work has been cited over 1,000 times — a body of research in antimicrobial materials that now underpins the company’s platform, which he architects while steering its commercial development.